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Purpose: We investigated bladder function, with a special focus on nonvoiding contractions (NVCs), in awake rats with chronic 
chemical cystitis and bladder outlet obstruction (BOO) by use of simultaneous registrations of intravesical and intraabdominal 
pressures. In addition, we tested the effects of tolterodine on the NVCs in these models.
Methods: A total of 20 female Sprague-Dawley rats were used in this study. In eight rats, chemical cystitis was induced by intra-
vesical instillation of HCl. Twelve rats were subjected to sham instillations or partial BOO. Four weeks after intravesical instilla-
tion or 2 weeks after partial BOO, cystometrograms were obtained by use of simultaneous recording of intravesical and intraab-
dominal pressure in all unanesthetized, unrestrained rats in metabolic cages. 
Results: A total of 17 rats survived. In the rats with acute injury by HCl, 50% showed detrusor overactivity (DO), which was not 
seen in the sham group. The cystitis group had lower DO pressure without a difference in DO frequency compared with the BOO 
group. After the administration of tolterodine, the cystitis group showed no difference in DO frequency or pressure, whereas the 
BOO group showed decreased values for both parameters. 
Conclusions: Our study showed that toleterodine produced no effect on DO during the filling phase in rats with chronic chem-
ical cystitisbut decreased the frequency and pressure of DO in rats with BOO. Clinically, studies are needed to improve the treat-
ment effect of anticholinergic drugs ininterstitial cystitis patients with overactive bladder.
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INTRODUCTION
Interstitial cystitis (IC) is one of the most commonly seen chron-
ic inflammatory diseases of the urinary bladderand is charac-
terized by a wide range of symptoms, including pelvic or lower 
abdominal pain and irritative voiding symptoms such as uri-
nary frequency, urgency, and nocturia [1-3]. Overlapping pat-
terns of lower urinary tract symptoms and pelvic pain are com-
mon in patients with IC [4], and these overlapping patterns cre-
ate challenges for clinical research and practice and warrant fur-
ther investigation of their causes, diagnosis, and effective treat-
ments. 
The conditions of IC and overactive bladder (OAB) share irrita-
tive voiding symptoms [1,4]. Theoretically, then, anticholinergic 
drugs could be considered to provide an alternate mechanism 
of action, which could decrease these embarrassing symptoms. 
In practice, however, many studies have shown that most IC 
patients do not respond appropriately to treatment with anti-
cholinergic medications, whereas OAB patients with benign 
prostatic hyperplasiarespond well [5,6]. Thus, we need to clarify 
the urodynamic findings and mechanismsin these two experi-
mental conditions in animal models. 
  The OAB syndrome is defined as urinary urgency, with or 
without urge incontinence, that is usually accompanied by uri-
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nary frequency and nocturia [7]. In other words, this urgency is 
regarded as a core symptom in diagnosis, which may correspond 
to detrusor overactivity (DO) during the filling phase in human 
urodynamic study [7,8]. Assuming that nonvoiding contractions 
(NVCs) interpreted on the basis of simultaneous changes in in-
traabdominal pressure (IAP) in an animal model can be used 
as a substitute parameter for DO in humans, the rat model of 
chemical cystitis and bladder outlet obstruction (BOO) may al-
low us to study the pathophysiology of different responsesto 
anticholinergic drugs. 
  In this study, we investigated bladder function, with a special 
focus on the NVCs, in awake rats with chemical cystitis and 
BOO by use of simultaneous registrations of intravesical and 
intraabdominal pressures. In addition, we tested the effects of 
tolterodine on the NVCs in these models.
MATERIALS AND METHODS
Animals and Study Design
A total of 20 female Sprague-Dawley rats (250 to 295 g; Orient 
Bio Inc., Seongnam, Korea) were used in this study. All experi-
mental animals and procedures were performed in accordance 
with the Guide for the Care and Use of Laboratory Animals of 
the National Institutes of Health and were approved by the local 
animal ethics committee. The rats were maintained under stan-
dard laboratory conditions with 12:12 hours light:dark cycles 
and free access to food pellets and tap water. In eight rats, 
chemical cystitis was induced by intravesical instillation of HCl. 
Twelve rats were subjected to sham instillations or partial BOO. 
Four weeks after intravesical instillation or 2 weeks after partial 
BOO, cystometrograms were obtained in all unanesthetized, 
unrestrained rats in metabolic cages. 
Induction of Cystitis
Rats were anesthetized with intraperitoneal ketamine (Ketamine, 
Yuhan Corp., Seoul, Korea; 75 mg/kg) and xylazine (Rompun, 
Bayer Korea Ltd., Seoul, Korea; 15 mg/kg intraperitoneally). 
Cystitis was induced by the intravesical instillation of 0.5 mL of 
0.4 N HCl [9]. Through an abdominal incision under anesthe-
sia, a 24-gauge needle with syringe was inserted into the dome 
of the bladder. After all of the urine was aspirated, HCl was in-
stilled into the bladder lumen for 90 seconds. The same volume 
of normal saline was instilled in the sham group. 
Procedures for Intravesical, Intraabdominal, and 
Intravenous Catheter Implantation
Three days before cystometry, catheterizations for simultaneous 
recordings of intravesical pressure (IVP) and IAP were per-
formed as described previously [10]. Briefly, after anesthesia, a 
polyethylene catheter (PE-50, Becton Dickinson, Parsipanny, 
NJ, USA) with a cuff was implanted into the dome of the blad-
der through an abdominal incision. To record IAP, an abdomi-
nal balloon (Latex, Dawoo Medical, Incheon, Korea) around 
the cuff of a catheter tip was placed proximal to the bladder and 
was tied to another catheter with silk tie. To deliver the anticho-
linergic agent during awake cystometry, a polyethylene catheter 
(PE-10) was inserted into a femoral vein, which was filled with 
heparinized (30 IU) saline. These catheters were then tunnelled 
through the subcutaneous space and exited the back of the ani-
mal and were anchored to the skin of the back. After surgery, 
each rat was caged individually and maintained in the same 
manner. 
Functional Evaluation
Cystometrograms were obtained in unanesthetized, unre-
strained rats in metabolic cages. The indwelling catheter to the 
bladder was connected to a two-way valve that was connected 
via a T-tube to a pressure transducer (Research Grade Blood 
Pressure Transducer, Harvard Apparatus, Holliston, MA, USA) 
and a microinjection pump (PHD22/2000 pump, Harvard Ap-
paratus). Another indwelling catheter connected to a fluid-filled 
abdominal balloon was connected to another pressure trans-
ducer to record the IAP. Micturition volumes were recorded by 
means of a fluid collector connected to a force displacement 
transducer (Research Grade Isometric Transducer; Harvard 
Apparatus). IVP, IAP, and micturition volumes were recorded 
continuously with Acq Knowledge 3.8.1 software and an MP150 
data acquisition system (BIOPAC Systems, Goleta, CA, USA) at 
a sampling rate of 50 Hz. The mean values from three repro-
ducible micturition cycles were used for evaluation. IAP was 
defined as the recorded balloon pressure minus the lowest bal-
loon pressure in each voiding cycle. Detrusor pressure (DP) 
was defined as IVP minus IAP. The IVP rises during the filling 
phase were defined as increments of IVP that exceeded 2 cm-
H2O from baseline, which was interpreted as DO if occurring 
without simultaneous similar changes in IAP and was inter-
pretedas abdominal straining if occurring with simultaneous 
similar changes in IAP. 122    www.einj.or.kr
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Investigated Urodynamic Parameters
Pressure- and volume-related parameters
These included basal pressure (BP; the lowest bladder pressure 
during filling), threshold pressure (TP; bladder pressure imme-
diately before micturition), maximum pressure (MP; maximum 
bladder pressure during the micturition cycle), micturition vol-
ume (MV; volume of expelled urine), residual volume (RV; re-
maining urine after voiding), bladder capacity (BC; MV+RV), 
and micturition interval (MI; intervals between micturition 
contractions).
DO-related parameters during the filling phase
These included time of filling phase (interval from the initiation 
of infusion through the tube and the point immediately before 
the initiation of micturition), frequency of abdominal strain-
ingper minute, frequency of DO per minute, and increased 
amplitude from base to peak of DO spike as IVP. These fre-
quencies were calculated on the basis of the time of filling phase. 
After cystometry, the animals were sacrificed by cervical dislo-
cation. The bladder and urethra were removed en bloc and sep-
arated at the level of the bladder neck, and the bladder was 
weighed.
Administration of Drug
During cystometry, room temperature saline was infused into 
the bladder at a rate of 10 mL.h
-1. Micturitions during intravesi-
cal saline infusion served as baseline values. After 0.2 mL tolt-
erodine (0.3 mg/kg) was injected intravenously, there was a 
30-minute observation period.
Statistical Analysis
The results are given as mean values±standard errors of the 
mean (SEMs). Normal distributions were confirmed by the 
Shapiro-Wilks’ W test. One-way analysis of variance with Tukey’s 
test was used to detect differencesin urodynamic parameters 
among the sham, cystitis, and BOO groups before drug admin-
istration, and paired testswere used to compare these parame-
ters between before and after drug administration in the same 
group. All analyses were performed with GraphPad Prism, ver. 
5.03, 2009 (GraphPad Software, San Diego, CA, USA). Statisti-
cal significance was considered at P<0.05, P<0.01, and P<0.001. 
All calculations were made based on n, which denoted the 
number of animals.
RESULTS
Comparison of Body Weights and the Ratio of Bladder to 
Body Weight
There wereno significant differences among the sham (266.7± 
6.7 g), cystitis (281.7±4.4 g), and BOO (261.0±6.0 g) groups in 
body weight at 2 weeks after intravesical instillations or ob-
struction surgery. However, the ratio of urinary bladder weight 
to body weight significantly increased in the BOO group 
(1.00±0.12) compared with the sham (0.43±0.02) andcystitis 
(0.45±0.03) groups. There was no significant difference be-
tween the sham and cystitis groups in that ratio (Fig. 1A). 
Comparison of Pressure-Related Parameters among the 
Three Groups and Effects of Tolterodine
The BOO group showed increased BP and TP by DP compared 
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Fig. 1. The ratio of bladder weight (mg) to body weight (g) (A) 
and the effects of tolterodine on pressure-related parameters in 
rats in the sham, chemical cystitis, and bladder outlet obstruc-
tion groups. (B) Basal pressure. (C) Threshold pressure. (D) 
Maximal pressure. Cystitis-control, micturition cycles without 
medication in the cystitis group; Cystitis-TD, micturition cycles 
after theadministration of tolterodine (3 mg/kg i.v.); Obs-con-
trol, micturition cycles without medication in the bladder outlet 
obstruction group; Obs-TD, micturition cycles after the admin-
istration of tolterodine (3 mg/kg i.v.); NS, not significant. Results 
are expressed as the mean±standard error of the mean. 
a)P
<0.05. 
b)P<0.01. 
c)P<0.001 (unpaired Student’s t-test); 
d)P
<0.05. 
e)P<0.01. 
f)P<0.001 (paired Student’s t-test). www.einj.or.kr    123
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with thecystitis and sham groups, but there were no significant 
differences in those values between the cystitis and sham groups. 
There were no significant differences in MP by DP among the 
three groups (Fig. 1B-D). 
  After the administration of tolterodine, the cystitis and BOO 
groups showed decreased MP by DP compared withthe values 
before medication (Fig. 1D). The BOO group showed decreased 
TP by DP, whereas the cystitis group showed no changes in this 
variable after medication. BP by DP did not change significant-
ly in either group with medication (Fig. 1B, C). 
Comparison of Volume-Related Parameters among the 
Three Groups and Effects of Tolterodine
There were no significant differences in any volume-related pa-
rameters before medication, including BC, MV, RV, and MI, 
among thesham, cystitis, and BOO groups (Fig. 2). 
  There were no significant changes in BC or MI after the ad-
ministration of tolterodine in either cystitisor BOO rats. Also, 
the cystitis group showed no changes in MV after medication, 
whereas values decreased in the BOO group. As for RV, the cys-
titis group also showed no changes despite higher values in the 
BOO group after medication (Fig. 2). 
Comparison of DO-Related Parameters between the Sham 
and Cystitis Groups and Effects of Toleterodine
The cystitis group showed the DO in 50% (3 of 6 rats), which 
was not seen in the sham group. Before theadministration of 
tolterodine, the cystitis group showed lower DO pressure, with-
out a difference in DO frequency, than did the BOO group. Af-
ter the administration, the cystitis group showed no difference 
in DO frequency orpressure, although the BOO group showed 
decreased values forboth parameters (Figs. 3, 4). 
DISCUSSION
Our study showed that tolterodine had no significant effect on 
Fig. 3. Representative tracings of intravesical and intraabdomi-
nal pressures showing total micturition cycles, before and after 
the administration of tolterodine (3 mg/kg i.v.), in rats with 
chemical cystitis and bladder outlet obstruction (BOO). (A) 
Chemical cystitis model. (B) BOO model. Pves, intravesical 
pressure; Pabd, intraabdominal pressure. 
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Fig. 2. The effects of tolterodine on volume-related parameters 
in rats in the sham, chemical cystitis, and bladder outlet ob-
struction groups. (A) Bladder capacity. (B) Micturition volume. 
(C) Residual volume. (D) Micturition interval. Cystitis-control, 
micturition cycles without medication in the cystitis group; 
Cystitis-TD, micturition cycles after theadministration of tolt-
erodine (3 mg/kg i.v.); Obs-control, micturition cycles without 
medication in the bladder outlet obstruction group; Obs-TD, 
micturition cycles after theadministration of tolterodine (3 mg/
kg i.v.); NS, not significant. Results are expressed as the mean± 
standard error of the mean. 
a)P<0.05 (paired Student’s t-test).
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urodynamic parameters, including pressure/volume and DO-
related variables, except MP in a chronic IC model. Only MP 
showed a decrease with treatment without changes in DO fre-
quency or pressure. This suggests that toleterodine may have an 
unfavorable effect on voiding without any effect on DO during 
the filling phase. In the BOO model, however, the drug resulted 
in adecrease inboth frequency and pressure of DO and some 
changes in pressure/volume parameters. The anticholinergic 
drug showed some effects on both the filling and voiding phases. 
IC is a chronic inflammatory disease of the bladder [1], but its 
etiology and pathogenesis remain obscure. It is characterized 
by irritative voiding symptoms and vague pain related to the 
bladder and shareswith OAB syndromeurinary urgency as a 
key symptom in diagnosis [1,4]. The urgency symptom is known 
to be correlated with the DO, which is defined as a urodynamic 
observation of involuntary detrusor contractions during the 
bladder-filling phase [7,8]. About 15% of patients with IC have 
been reported to have spontaneous DO as measured by urody-
namic testing [11]. The treatment of this DO has incorporated 
the application of anticholinergic drugs, but many clinical re-
ports have shownthat these drugs are ineffective in many pa-
tients with IC [5,6]. There havebeen few reports directly show-
ing the effects of anticholinergic drugs on urodynamic results, 
including objective report of DO in an awake animal IC model. 
According to our results, DO was not affected by the anticho-
linergic drug in the IC model, unlike in the BOO model. Such 
study to find the cause of the ineffectiveness in an animal model 
is important to improve our understanding of these drugs and 
to find possible alternative treatments. 
  The uncertainty over the benefit of anticholinergic drugs in 
IC appears to stem from two separate factors of unclear diag-
nostic criteria and etiology or pathophysiology. In the diagnosis 
of IC, after ruling out other obvious pathology and overlapping 
syndromes through an extensive and specific series of tests [12], 
the exclusion of other often confused diseases is still encour-
aged, because there are no definitive diagnostic tests. Since the 
National Institute for Diabetes and Diseases of the Kidney (NI-
DDK) reported the diagnostic criteria for IC in 1990 [13], the 
definitions and terminology have undergone some changes. 
Different organizations have proposed different terms, such as 
painful bladder syndrome or bladder pain syndrome [14,15]. 
Enigmatic pain related to the bladder was emphasized more 
than the other symptoms in these reports [3,14]. However, be-
cause these small changes in diagnostic criteria can result in 
noticeably different patient groups being studied, we need to 
unify the terms or definitions and focus on how to delineate the 
patients accurately by use of accurate diagnostic criteria inter-
nationally. The heterogeneous characteristics of IC subgroups 
could be the starting obstacle in finding a solution to the inef-
fectiveness of anticholinergic drugs. It will be important to find 
a subgroup of IC patients who respond well to this drug or to 
determine how to use this drug as a palliative agent. 
  Second, several decades of research on IC has revealed that 
inflammation, as determined by the presence of cytokines, che-
mokines and mast cells, may have vital role in the pathogenesis 
Fig. 4. Representative tracings of intravesical and intraabdomi-
nal pressures showing minute changes in detrusor overactivity 
(DO) before and after the administration of tolterodine (3 mg/
kg i.v.) in rats with chemical cystitis and bladder outlet obstruc-
tion (BOO). (A) Chemical cystitis model before medication. (B) 
Chemical cystitis model after injection. (C) BOO model before 
medication. (D) BOO model after injection. (E) Changes in DO 
frequency. (F) Changes in DO pressure. Cystitis-control, mictu-
rition cycles without medication in the cystitis group; Cystitis-
TD, micturition cycles after the administration of tolterodine; 
Obs-control, micturition cycles without medication in the blad-
der outlet obstruction group; Obs-TD, micturition cycles after 
the administration of tolterodine; NS, not significant; Pves, in-
travesical pressure; Pabd, intraabdominal pressure. Results are 
expressed as the mean±standard error of the mean. 
a)P<0.05 
(unpaired Student’s t-test); 
b)P<0.05 (paired Student’s t-test).
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of this disease [16,17]. Although it is suggested that increased 
permeability of or neuropathic pain in the bladder mucosa re-
sults in OAB through the activation of afferent reflex circuitry 
[18-20], our limited understanding of the fundamental mecha-
nisms causing OAB in IC has continued to frustrate efforts 
aimed at its treatment. The detailed mechanism needs further 
elucidation. 
  Our proposed model of chronic chemical cystitis showed the 
characteristics of OAB in view of DO-related parameters. Our 
modelshowed DO in 50% of the rats, even with no increased 
BP, TP, or MP and no decreased BC, MV, RV, or MI compared 
with the control rats. These animals at 4 weeks did not show 
differences compared with animals at 2 weeks in our previous 
study [21]. Our model of BOO also showed characteristics 
similar to the results of previous studies with BOO. The BOO 
rats showed an increased ratio of bladder to body weight, in-
creased BP, and increased TP, but no increases in BC, MI, or 
RV. After theadministration of tolterodine, the BOO model 
showed a decrease inTP, MP, and DO pressure/frequency and 
an increase in RV, corresponding to the original effects of that 
drug. 
  In the obstructed bladder, supersensitivity of the detrusor 
muscle secondary to denervation was found to play a predomi-
nant pathophysiologic role in OAB [22,23]. This has been sug-
gested to be caused by bladder overdistention resulting from 
BOO [24]. Clinically, DO in men with OAB responds well to 
antimuscarinics, which is similar the results of our study [25]. 
An anticholinergic agent is a substance that blocks the acetyl-
choline of a neurotransmitter by competitive inhibition in neu-
rons of the central and peripheral nervous system. This is known 
to reduce the effects mediated by acetylcholine on muscarinic 
receptors in those neurons [26]. We suspect that the different 
response between BOO and IC is caused by the basic difference 
in the pathophysiologic characteristics of the bladder in these 
two conditions, which needs to be elucidated further in future 
studies. Clinically, we also need further study to improve the 
treatment effect of anticholinergic drugs inIC patients with OAB.
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